Related Experiment Video
Updated: Apr 3, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.9K
ADIPSIC DIABETES INSIPIDUS: A REVIEW.
Summary
Adipsic diabetes insipidus (ADI) is a rare condition combining central diabetes insipidus with impaired thirst. Early diagnosis and management of ADI are crucial for patient safety and effective outpatient care.
Area of Science:
- Endocrinology
- Nephrology
- Internal Medicine
Background:
- Adipsic diabetes insipidus (ADI) is a rare disorder characterized by central diabetes insipidus (CDI) and a blunted or absent thirst response.
- Patients with ADI face significant risks of morbidity and mortality, posing diagnostic and management challenges.
Purpose of the Study:
- To provide an updated overview of the clinical scenario of ADI.
- To highlight diagnostic and management strategies for this rare condition.
Main Methods:
- A PubMed literature search was conducted using terms related to ADI, adipsia, and thirst.
- Relevant articles were identified to synthesize current knowledge on ADI.
Main Results:
- ADI has been reported in approximately 100 patients, with limited literature primarily consisting of case reports and expert opinions.
- Diagnosis involves confirming CDI and assessing thirst response to hypertonic stimuli.
- Patients with ADI often experience severe hypernatremia, obesity, sleep apnea, and venous thromboembolism, alongside increased mortality risk.
Conclusions:
- Managing ADI patients presents complex clinical challenges.
- Prompt identification of thirst disorders in CDI patients is essential.
- Appropriate management strategies can enable safe outpatient care for individuals with ADI.
Related Concept Videos
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.8K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.8K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.0K
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:06Oral Hypoglycemic Agents: Glinides
958
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
958
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:20Pathophysiology of Diabetes
4.4K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.4K